Healthcare & Pharma
Healthcare and specialty-pharma names in Canada often combine distribution platforms, cash-rich balance sheets and acquisition-led growth. We watch revenue and EBITDA growth, how well that converts to cash, and the discipline of capital allocation.
Reports in Healthcare & Pharma
Knight Therapeutics
A cash-rich pan-Latin-American and Canadian specialty-pharma platform now growing revenue and EBITDA quickly.
Apotex Health Corp.
Canada's homegrown generic-drug champion, newly public on the TSX, that is shifting its mix toward specialty generics, biosimilars and branded products.
Aurora Cannabis Inc.
An Edmonton cannabis producer that has turned itself into a debt-free global medical-cannabis supplier, and is now the target of a hostile takeover bid from Curaleaf.
Bausch Health Companies Inc.
A heavily indebted specialty-pharma and medical-device group, anchored by gastrointestinal drugs and a majority stake in Bausch + Lomb, that generates strong cash flow but lives under a very large debt load.
Bausch + Lomb Corporation
A global eye-health company spanning contact lenses, eye-care consumer products, ophthalmic drugs and surgical devices. It is majority-owned by Bausch Health and carries a heavy debt load.
Canopy Growth Corporation
Canada's former cannabis bellwether, now a much smaller, still loss-making producer and vaporizer maker trying to reach positive EBITDA.